IMM 1.58% 46.8¢ immutep limited

Ann: Immutep announces European Patent Grant for LAG525, page-2

  1. 475 Posts.
    lightbulb Created with Sketch. 544
    PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

    Actual Study Completion Date :September 17, 2020

    Primary Outcome Measures :Clinical Benefit Rate (CBR) at 24 weeks of PDR001+LAG525 by tumor type in multiple solid tumors and lymphoma [ Time Frame: 24 weeks ]Clinical Benefit Rate (CBR) is defined as the percentage of participants with a best overall response of Complete Response (CR), Partial Response (PR) and Stable Disease.

    28 weeks since completion of trial.....
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
46.8¢
Change
-0.008(1.58%)
Mkt cap ! $405.5M
Open High Low Value Volume
48.0¢ 48.0¢ 46.8¢ $386.0K 810.2K

Buyers (Bids)

No. Vol. Price($)
5 51652 46.5¢
 

Sellers (Offers)

Price($) Vol. No.
47.0¢ 80671 4
View Market Depth
Last trade - 10.26am 02/12/2021 (20 minute delay) ?
(live)
Last
47.0¢
  Change
-0.008 ( 1.05 %)
Open High Low Volume
48.0¢ 48.5¢ 46.5¢ 236894
Last updated 10.41am 02/12/2021 (live) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.